Form 4: Black Diamond Therapeutics Director Opts for Stock Compensation, Increasing Stake

Prakash Raman, a Director at Black Diamond Therapeutics, Inc. (BDTX), acquired 5,526 shares of common stock by electing to receive equity in lieu of cash compensation for his annual services.

Summary

• Prakash Raman, a Director of Black Diamond Therapeutics, Inc. (BDTX), acquired 5,526 shares of the company's common stock.
• The transaction occurred on June 20, 2025, with shares valued at $2.33 each, based on the closing market price on June 18, 2025.
• This acquisition was made in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, where Mr. Raman elected to receive shares instead of cash for his annual services as a non-employee director.
• Following this transaction, Mr. Raman's direct beneficial ownership of Black Diamond Therapeutics common stock increased to 22,519 shares.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, particularly in lieu of cash compensation, is generally viewed positively as it aligns the director's interests with those of shareholders and indicates confidence in the company's equity value.

Positives

• The acquisition of shares by a director in lieu of cash compensation demonstrates alignment of interests between management and shareholders, potentially signaling confidence in the company's future performance.
• An increase in insider ownership can be viewed positively by investors as it suggests a vested interest in the company's long-term success.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely focused on an insider transaction.

Industry Context

The practice of non-employee directors electing to receive equity compensation in lieu of cash is a common corporate governance strategy across various industries, including biotechnology, to align director incentives with shareholder interests and conserve cash.

Corporate Governance

Related Party Transactions

• Prakash Raman, a Director of Black Diamond Therapeutics, Inc., acquired shares from the company as compensation for his services, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively by shareholders as it increases insider ownership, potentially signaling confidence in the company's future and aligning director interests with shareholder returns.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Prakash Raman, Director Compensation, Stock Acquisition, Insider Trading, SEC Form 4, Equity Compensation